Cameron Joseph

3 weeks ago | csmonitor.com | Cameron Joseph

Democrats just won the first big election since President Donald Trump returned to the White House, while running well ahead of their 2024 numbers in two special congressional races – early signs that liberals’ white-hot fury at the president may help their chances in next year’s midterm elections.

3 weeks ago | spherixglobalinsights.com | Cameron Joseph

Gastroenterologists are enthusiastic about Tremfya’s subcutaneous induction option in Crohn’s disease, a key potential brand differentiator, according to Spherix Global Insights. EXTON, PA., March 28, 2025 – The treatment landscape for Crohn’s disease continues to evolve with the recent FDA approval of Johnson and Johnson Innovative Medicine’s Tremfya (guselkumab).

4 weeks ago | spherixglobalinsights.com | Cameron Joseph

While interest in BMS’s pipeline asset is strong, some prescribers are underwhelmed by ACR20 endpoint. EXTON, PA, March 27, 2025 – In late 2024, Bristol Myers Squibb announced positive topline results from its pivotal Phase 3 trials, POETYK PsA-1 and PsA-2, evaluating Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA). Both trials met their primary endpoint, with significantly more Sotyktu-treated patients achieving an ACR20 response at Week 16 compared to placebo (54% vs.

4 weeks ago | spherixglobalinsights.com | Cameron Joseph

Hematologists remain undecided on the long-term role of newly launched hemophilia therapies, particularly as the industry awaits word on Sanofi’s fitusiran by the end of March. [Exton, PA, March 26, 2025] – The hemophilia treatment landscape is rapidly evolving, with newly launched therapies and gene therapies joining factor replacement therapies,  Hemlibra, and Altuvio to create new options.

4 weeks ago | csmonitor.com | Cameron Joseph

The first big election since President Donald Trump’s 2024 victory has arrived – and Elon Musk is front-and-center. Voters in Wisconsin, one of the nation’s most critical battleground states, will decide on April 1 whether their state Supreme Court will have a liberal or conservative majority. The technically nonpartisan race has turned into a high-stakes partisan proxy fight with national ramifications.